$XBI $123.84 +0.47%
Covid Updates
$COCP +4.5% Cocrystal Pharma to Present Data from its Oral and Intranasal COVID-19 Therapeutics Programs at the World Antiviral Congress 2021 source
$PFE +0.1% & BNTX +6.3% Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine source
Pipeline Updates
$MTCR +3.2% Metacrine Reports Interim Results for MET642 Phase 2a Trial in Patients with NASH and Announces a Strategic Re-Prioritization of Its Clinical Development Programs source
$HZNP +2.4% Newly Published Data Continue to Support Long-Term Efficacy of TEPEZZA® (teprotumumab-trbw) for Thyroid Eye Disease (TED) source
$SCYX +3.8% SCYNEXIS Pivotal Phase 3 VANISH-303 Trial Results Published in Clinical Infectious Diseases Demonstrate Significant Superiority of Ibrexafungerp Over Placebo for Treatment of Vaginal Yeast Infection source
$CALA 0.0% Calithera Biosciences to Present First Clinical Data from Development Program for Arginase
Inhibitor CB-280 at NACFC 2021 source
$SIOX +9.8% Sio Gene Therapies Announces Granting of FDA Fast Track Designation for Investigational AXO-AAV-GM1 (AAV9-GLB1) Gene Therapy in Patients with GM1 Gangliosidosis source
$KPTI +1.3% Karyopharm Announces Dosing of First Patient in a Phase 2 Study Investigating Oral Eltanexor in HMA Refractory Myelodysplastic Syndrome source
$GILD +0.2% Gilead Presents Long-Term Switch Data Reinforcing Biktarvy® as a Treatment Option for a Broad Range of People Living With HIV source
$PDSB +3.9% PDS Biotech Provides Update on National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination source
$NTLA +3.9% Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis source
$FREQ -1.5% Frequency Therapeutics Announces First Subject Dosed in FX-322 Phase 2b Acquired Sensorineural Hearing Loss (SNHL) Study and FDA Agreement on Speech Perception as Primary Endpoint source
$MTNB +2.6% Matinas BioPharma Initiates Dosing in Phase 1 Study of Potential First Oral Aminoglycoside Antibiotic Drug MAT2501 source
$ALXO -1.9% ALX Oncology Announces First Patient Dosed in ASPEN-05, a Phase 1/2 Study of Evorpacept in Combination with Venetoclax and Azacitidine in Patients with Acute Myeloid Leukemia source
$UTHR -0.8% United Therapeutics Details New Data Presented at CHEST Annual Meeting 2021 source
$SIOX +9.8% Sio Gene Therapies Announces Positive Interim Safety and Biomarker Data from Ongoing Phase 1/2 Clinical Study of AXO-AAV-GM1 Gene Therapy in GM1 Gangliosidosis source
Financial & Business Updates
$ISEE +6.7% Iveric Bio Announces Proposed Offering of Common Stock source
$ADMA +9.0% ADMA Biologics Announces Pricing of Public Offering for $50 Million of Common Stock source
Posted by JM
Коментарі